Minerva Neurosciences Appoints New Chief Business Officer, Counsel

Minerva Neurosciences ( (NERV) ) has shared an update.

On March 30, 2026, Minerva Neurosciences reached a settlement agreement with longtime executive Geoffrey Race, under which he resigned as president effective March 31, 2026, and stepped down as a director of subsidiary Mind-NRG. The package provides salary and pension in lieu of a 12-month notice period, a pro-rated 2026 bonus and additional severance, benefits, and legal fee reimbursement, while fully vesting his stock options and extending their exercise window to January 1, 2030.

To maintain continuity, Minerva simultaneously signed a consultancy agreement with Race on March 30, 2026, under which he will advise the company from April 15, 2026, to April 14, 2027, at an hourly rate with a minimum monthly commitment and potential eligibility for additional stock options. The structure underscores the board’s desire to retain Race’s institutional knowledge during a sensitive phase of the company’s clinical and corporate development, while formally transitioning day-to-day leadership responsibilities.

On April 2, 2026, Minerva announced that James (Jim) O’Connor would join as Chief Business Officer and General Counsel, with his appointment effective April 21, 2026, marking a key leadership refresh at a pivotal stage for the company’s lead drug roluperidone. O’Connor brings more than two decades of legal and business experience across life sciences, technology, and industrial sectors, including significant financing, FDA interaction, and strategic transaction expertise that Minerva’s board and CEO see as critical as the company prepares for its next planned Phase 3 trial.

The leadership changes reflect Minerva’s effort to strengthen its business, legal, and transactional capabilities while preserving strategic continuity through Race’s consulting role. For investors and other stakeholders, the move signals a sharpening focus on executing late-stage clinical strategy and potential commercialization pathways for roluperidone in an area of high unmet need, even as the company navigates the inherent risks of CNS drug development and capital requirements.

The most recent analyst rating on (NERV) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Spark’s Take on NERV Stock

According to Spark, TipRanks’ AI Analyst, NERV is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals provide some offset due to strength versus longer-term moving averages and a positive MACD, while valuation remains constrained by negative earnings. A recent positive Phase 3 trial-plan update adds modest support but is still high-risk and long timeline.

To see Spark’s full report on NERV stock, click here.

More about Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system diseases. Its lead program is roluperidone, which targets the negative symptoms of schizophrenia, with the company aiming to offer improved therapeutic options for patients facing significant unmet medical needs.

Based in Burlington, Mass., and listed on Nasdaq under the ticker NERV, Minerva concentrates on advancing late-stage clinical assets in schizophrenia. The company’s strategy centers on executing pivotal trials and building the operational, financial, and clinical infrastructure needed to potentially bring novel CNS therapies to market.

Minerva operates in a highly competitive neuropsychiatric drug development space, where success in Phase 3 trials and subsequent regulatory approvals are critical to value creation. Its focus on negative symptoms of schizophrenia, an area without approved therapies, positions the company to address a niche but potentially meaningful commercial opportunity if its lead candidate succeeds clinically and regulatorily.

Average Trading Volume: 215,272

Technical Sentiment Signal: Buy

Current Market Cap: $242.3M

For a thorough assessment of NERV stock, go to TipRanks’ Stock Analysis page.